Breakpoint Quiz

[Danny Hosford]

Abreakpoint ramps to unrealistically high numbers. This test commonly has to be stopped manually or automatically as thresholds start to fail. When these problems appear, the system has reached its limits.

Once the breakpoint runs and the system limits have been identified, you can repeat the test after the tuning exercise to validate how it impacted limits. Repeat the test-tune cycle until the team is satisfied.

Avoid breakpoint tests in elastic cloud environments.

An elastic cloud environment changes to reflect the needs of an organization, adjusting resources such as CPU, memory, and storage consumption as needed. An elastic environment may grow during breakpoint tests, finding only the limit of your cloud account bill. If you are running a breakpoint test on a cloud environment, turning off elasticity on all the affected components is strongly recommended.

Run breakpoint tests only when the system is known to perform well under all other test types.

The breakpoint test might go too far if the system performs poorly with other load testing types.

The breakpoint test is straightforward. The load slowly ramps up to a considerably high level. It has no plateau, ramp-down, or other steps. And it generally fails before reaching the indicated point.

k6 offers two ways to increase the activity: increasing VUs or increasing throughput (open and closed models). Different from other load test types, which should be stopped when the system degrades to a certain point, breakpoint load increases even as the system starts to degrade. That makes it recommendable to use ramping-arrival-rate for a breakpoint test.

I'm trying to put breakpoints into the GoogleAppEngine sources (SDK 1.7.0) but IDEA Ultimate (11.0.2) just keeps telling me Warning: No executable code found at line 482 in class com.google.appengine.api.memcache.AsyncMemcacheServiceImpl.

My jar files are added as a project library to the module, and my sources are attached to this library. I was playing around with module dependencies as well, but without any luck. Finally, I decided to put this library into Compile scope, but that was a bad idea since the SDK provides these jars at runtime, so I decided to fall back to Provided scope.

I also played with the export checkbox on the module dependencies tab, but I think this is irrelevant, according to the web help, export is only important when you have dependent modules and you want to make your library available in these modules as well.

I edited my question due to my javap experiments below: It seems that the classes and the sources are NOT out of sync. I checked out the 1.7.0 related revision from SVN, and I'm using the 1.7.0 SDK, so these should not be out of sync at all.

I had faced similar problem while debugging in intellij. I wasn't able to put breakpoint at one of the code snippet, then i changed the line number of the code and after that i was able to put breakpoint. Looks like a bug in intellij or some caching issue.

I found some other cases where people reported that IDEA says "No executable code found". A common pattern is that they were trying to debug code that has been built without debug information. Check that you are compiling with the "-g" flag (or equivalent) set. Use javap to see if there is debug information in the .class file(s).

The question is rather old but I thought my experience might help someone in the future. In my case I was trying to debug code that was not compiled with debug information. I am using maven in which the original parent pom file before modification looked something like below in the build section.

The essence of the problem is that the JVM executes a class file (either simple class or a class loaded from jar from the class path) which DOES NOT MATCH the source being used by debugger.Once this is understood, the solution is simple: make sure that the source represents the class being executed.So, to fix the problem you can refresh-synchronize sources to classes, etc.

I had a similar problem and it was caused by a mistake in my Tomcat configuration, under the Deployment tab, the "Deploy at the server startup". I had accidentally changed it to a very similar project with ":war exploded". When I changed it back, it worked fine.

In my case i was debugging remotely, found out that the version of code on the remote server and Intellij was not in sync. I re-build the latest code locally, placed the same change on remote server and it worked for me.

You can try out few more possible solutions that could be specific to your problems suggested by JetBrains.Impossible to debug "Warning: no executable code found at line."

You should stop your server, increase the memory settings on the options that are passed to java and restart your server. Check logs to ensure you don't get a report such as "running in low memory mode".

I had the same issue using debug configuration in my case Tomcat.I tried all above, but nothing.when I just reconfigured the Tomcat (debug > edit configuration > remove the tomcat > add it again from scratch) it was finally working :)

Check your disc space and free up some memory. If you are running low on disc space, even if your server is not on "low memory mode", intelliJ would not allocate the space to cache the classes required for debugging. As a result it won't allow you to set the break-point.

The site is secure.

The ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

The agency will update this information at least every six months through publication of a notice on this page. Annually FDA will publish a compilation of these notices on the Federal Register for public comment. Changes could include:

To ensure that the most up-to-date STIC are available, holders of approved drug applications had until December 13, 2018, to remove the STIC information and related information from the labeling of approved systemic antibacterial and antifungal drugs and replace it with a reference to information on these new pages. FDA has published a final guidance to further explain these requirements.

Enabling physicians to select appropriate antibacterial or antifungal drugs is critical to individual patient care and public health. Generally, physicians rely on antimicrobial susceptibility testing (AST) performed by clinical microbiology laboratories to help choose an appropriate treatment. STIC are the criteria used to interpret AST results. STIC identify whether bacteria or fungi are considered susceptible or resistant to a particular drug. Bacteria and fungi change over time. When this occurs, STIC need to be updated. Laboratories and AST device manufacturers need to be able to use up-to-date interpretive criteria for the reports provided to physicians to inform appropriate treatment choices. Up-to-date AST results are an important component in addressing the problem of antimicrobial resistance.

Before the Cures Act was signed into law, each antibacterial and antifungal drug manufacturer was responsible for updating its drug labeling with new STIC and each device manufacturer updated its device algorithm and labeling only after the drug labeling was updated. This process of updating and re-updating labeling for hundreds of drug and device products was an inefficient means to provide updated information to the practicing community.

After publishing a Federal Register notice on October 30, 2017, requesting publicly available information illustrating how an SDO fulfills these requirements, FDA has determined that the Clinical and Laboratory Standards Institute (CLSI) fulfills these statutory requirements at this time.

FDA recognizes consensus standards for performance standards, methods standards, and quality control parameter standards for antimicrobial susceptibility testing. Occasionally, consensus standards for methods and quality control parameters may not be established by an SDO at the time a new drug is approved. If appropriate, FDA will list acceptable methods and quality control information for the drug along with the STIC identified for such drug.

Susceptible (S) is a category defined by a breakpoint that implies that isolates with a minimal inhibitory concentration (MIC) at or below or a zone diameter at or above the susceptible breakpoint are inhibited by the usually achievable concentrations of antimicrobial agent when the dosage recommended to treat the site of infection is used, resulting in likely clinical efficacy.

Susceptible-dose dependent (SDD) is a category defined by a breakpoint that implies that susceptibility of an isolate depends on the dosing regimen that is used in the patient. To achieve drug exposure likely to be clinically effective against isolates for which the susceptibility testing results (either MICs or zone diameters) are in the SDD category, it is necessary to use a dosing regimen (e.g., higher doses, more frequent doses, and/or extended infusion time) that results in higher or prolonged drug exposure than that achieved with the dose that was used to establish the susceptible breakpoint.

Intermediate (I) is a category defined by a breakpoint that includes isolates with MICs or zone diameters within the intermediate range that approach usually attainable blood and tissue levels and/or for which response rates may be lower than for susceptible isolates. The I category also includes a buffer zone for inherent variability in test methods, which should prevent small, uncontrolled, technical factors from causing major discrepancies in interpretations, especially for drugs with narrow pharmacotoxicity margins.

Resistant (R) is a category defined by a breakpoint that implies that isolates with an MIC at or above or a zone diameter at or below the resistant breakpoint are not inhibited by the usually achievable concentrations of the agent with recommended dosage schedules and/or that demonstrate MICs or zone diameters that fall in the range in which specific microbial resistance mechanisms are likely, and clinical efficacy of the agent against the isolate has not been reliably shown in clinical studies.

3a8082e126